* COR Therapeutics Inc., of South San Francisco, said the FDAaccepted for filing and review its new drug application for Integrilin.COR is seeking approval to market the drug to help prevent acutecardiac ischemic complications in patients undergoing percutaneoustransluminal coronary angioplasty. (See BioWorld Today, April 4,1996, p. 1.)
(c) 1997 American Health Consultants. All rights reserved.